USFDA Inspection at Pharmaceutical Formulation Facility

Intimation for appointment of Mr. Narotam Kumar Juneja

Intimation for Closure of trading window

Intimating the Resignation of Mr. Shantanu Yeshwant Nalavadi

Intimation w.r.t. redemption of 79,800 unrated, unlisted, redeemable, non-convertible debentures (NCDs) by material subsidiary viz. Panacea Biotec Pharma Limited

Signing of Definitive Agreements with Mankind Pharma for sale of pharmaceutical formulation brands of PBPL

Intimation of Board Meeting

Closure of Trading Window

Party disclosure for the half year ended September 30, 2021

Clarification on Extension of Repayment Date of Series 1A NCDs